Brokerages predict that Abeona Therapeutics Inc (NASDAQ:ABEO) will report $240,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Abeona Therapeutics’ earnings, with estimates ranging from $200,000.00 to $300,000.00. Abeona Therapeutics posted sales of $260,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 7.7%. The business is expected to announce its next earnings results on Friday, March 30th.
On average, analysts expect that Abeona Therapeutics will report full year sales of $240,000.00 for the current year, with estimates ranging from $800,000.00 to $900,000.00. For the next fiscal year, analysts anticipate that the business will report sales of $1.21 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%.
A number of hedge funds have recently modified their holdings of ABEO. Geode Capital Management LLC lifted its holdings in Abeona Therapeutics by 2.4% in the 1st quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 4,588 shares during the period. Family Management Corp lifted its holdings in Abeona Therapeutics by 50.0% in the 3rd quarter. Family Management Corp now owns 36,000 shares of the biopharmaceutical company’s stock worth $614,000 after buying an additional 12,000 shares during the period. Ardsley Advisory Partners lifted its holdings in Abeona Therapeutics by 33.3% in the 2nd quarter. Ardsley Advisory Partners now owns 60,000 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 15,000 shares during the period. State of Wisconsin Investment Board purchased a new stake in Abeona Therapeutics in the 2nd quarter worth approximately $122,000. Finally, Rhumbline Advisers purchased a new stake in Abeona Therapeutics in the 2nd quarter worth approximately $190,000. Institutional investors own 41.95% of the company’s stock.
Abeona Therapeutics (NASDAQ:ABEO) opened at $15.85 on Friday. The company has a market capitalization of $699.29, a PE ratio of -24.02 and a beta of 2.23. Abeona Therapeutics has a 1 year low of $4.49 and a 1 year high of $22.75.
COPYRIGHT VIOLATION NOTICE: This article was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/23/abeona-therapeutics-inc-abeo-expected-to-post-quarterly-sales-of-240000-00.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.